Current Drug Managements of Wilson’s Disease: From West to East

Author(s): Wen-Jie Li, Chen Chen, Zhi-Fei You, Ren-Min Yang, Xiao-Ping Wang.

Journal Name: Current Neuropharmacology

Volume 14 , Issue 4 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Wilson’s disease (WD), also called hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism characterized by the multiple mutations in the ATP-ase 7B gene of chromosome 13q. About half of the WD patients have neurological or psychiatric symptoms. As WD is a kind of medicable or nearly curable neurodegenerative disease in the field of medicine, early consideration/examination and without delay/ life-long treatment usually lead to better prognoses. The drugs, also named as anticopper agents, are commonly used in clinics including D-penicillamine, trientine, sodium dimercaptosuccinate, dimercaptosuccinic acid, zinc and tetrathiomolybdate. This provides detailed reviews about these medicines.

Keywords: D-penicillamine, dimercaptosuccinic acid, hepatolenticular degeneration, sodium dimercaptosuccinate, tetrathiomolybdate, trientine, Wilson’s disease, zinc.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 4
Year: 2016
Page: [322 - 325]
Pages: 4
DOI: 10.2174/1570159X14666151130222427
Price: $65

Article Metrics

PDF: 43
HTML: 2
EPUB: 1
PRC: 1

Special-new-year-discount